β-CGRP, human |
| Catalog No.GC33595 |
β-CGRP, human is one of calcitonin peptides, acts via the complex of calcitonin-receptor-like receptor (CRLR) and receptor-activity-modifying protein (RAMP), with IC50s of 1 nM and 300 nM for CRLR/RAMP1 and CRLR/RAMP2 in cells.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 101462-82-2
Sample solution is provided at 25 µL, 10mM.
β-CGRP, human is a neuropeptide hormone produced by the calcitonin gene-related peptide family, which forms a complex with calcitonin receptor-like receptors CRLR and RAMP (CRLR/RAMP1: IC50 =1nM; CRLR/RAMP2: IC50 = 300nM) [1]. β-CGRP, human activates the adenylate cyclase-cAMP-PKA signaling pathway by binding to the CGRP receptor complex (composed of CALCRL and RAMP1), inducing physiological effects such as vascular smooth muscle relaxation, neuronal excitation regulation, and inflammation mediation [2-3]. β-CGRP, human is mainly used in research on migraine, cardiovascular regulation, neuroinflammation, and pain [4].
In A549 cells, β-CGRP, human (0.1-10nM; 24h) markedly increases heart rate in rats, and reduces IL-1β-induced production of IL-8 and MCP-1 [5]. In endothelial cells, β-CGRP, human (1-30μM; 24h) induces concentration-dependent relaxation of pre-contracted human intracranial arterial ring segments [6].
References:
[1]. McLatchie L M, Fraser N J, Main M J, et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor[J]. Nature, 1998, 393(6683): 333-339.
[2]. Bonura A, Brunelli N, Marcosano M, et al. Calcitonin gene-related peptide systemic effects: embracing the complexity of its biological roles—a narrative review[J]. International Journal of Molecular Sciences, 2023, 24(18): 13979.
[3]. Tsukiji J, Sango K, Udaka N, et al. Long-term induction of β-CGRP mRNA in rat lungs by allergic inflammation[J]. Life sciences, 2004, 76(2): 163-177.
[4]. Shen Y T, Pittman T J, Buie P S, et al. Functional role of α-calcitonin gene-related peptide in the regulation of the cardiovascular system[J]. The Journal of Pharmacology and Experimental Therapeutics, 2001, 298(2): 551-558. [1].
[5]. Li W, Hou L, Hua Z, et al. Interleukin‐1β induces β‐calcitonin gene‐related peptide secretion in human type II alveolar epithelial cells[J]. The FASEB journal, 2004, 18(13): 1603-1605.
[6]. Jansen-Olesen I, Jørgensen L, Engel U, et al. In-depth characterization of CGRP receptors in human intracranial arteries[J]. European journal of pharmacology, 2003, 481(2-3): 207-216.
| Cell experiment [1]: | |
Cell lines | A549 cells |
Preparation Method | A549 cells were stimulated with either fresh medium, β-CGRP, human of indicated concentrations or β-CGRP, human plus IL-1ß for 24h; supernatants were collected and assayed for IL-8 or MCP-1 by ELISA. |
Reaction Conditions | 0.1-10nM; 24h |
Applications | In A549 cells, β-CGRP, human markedly increases heart rate in rats, and reduces IL-1β-induced production of IL-8 and MCP-1. |
References: | |
| Cas No. | 101462-82-2 | SDF | |
| Canonical SMILES | Ala-Cys-Asn-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Met-Val-Lys-Ser-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH2(Disulfide bridge: Cys2-Cys7) | ||
| Formula | C162H267N51O48S3 | M.Wt | 3793.41 |
| Solubility | Soluble in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 263.6 μL | 1.3181 mL | 2.6362 mL |
| 5 mM | 52.7 μL | 263.6 μL | 527.2 μL |
| 10 mM | 26.4 μL | 131.8 μL | 263.6 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 32 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *















